Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly ...
Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences is advancing the development of its promising drug tuspetinib as part ...
A layman reading the latest anti-money-laundering (AML) figures [1] issued by the Institute of Chartered Accountants in England and Wales (ICAEW) might ...
Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.
Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th – – Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r ...
On 10/10/24, FinCEN assessed a record $1.3 billion penalty against TD Bank for BSA violations. This unprecedented penalty ...
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Kura Oncology (KURA – Research Report) yesterday and set a ...
Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...
Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...
Without perpetual screening, the majority of money mules are likely to go undetected. This content is provided by an external author without editing by Finextra. It expresses the views and opinions of ...
About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...